IMU

1.89%

5.2¢ imugene limited

Ann: FDA IND APPROVAL FOR ONCOLYTIC VIROTHERAPY VAXINIA, page-36

First 36 Last

Share
Profile

Follow
Steini

12,411 Posts.

3790

13/12/21

12:59

Post #: 58255720
Share

Originally posted by PilbaraBoy: ↑

You'd think so right plovagurl????

But remember - this is the pathetic farce known as the ASX that we are dealing with (as well as imbecile so called "investors" that barely understand what Telstra & Woolworths do, let alone a biotech company researching cutting-edge cancer immuno-oncology therapies.)

Let me recap: In just the past 4 weeks Imugene has:

* Announced a Clinical Trial Agreement with Merck & Pfizer.
* Obtained S&P admittance into the ASX200.
* Received $6 million in cash (via conversion of 150 million IMUOB options).
* Received FDA IND approval for its second Oncolytic Virus (Vaxinia).
* Received FDA IND approval for an additional Phase 2 clinical trial for HER-Vaxx

Any other biotech company, on any other index in the world (with a comparable share price & market cap to Imugene) would have seen it's share price hit $1.00 as result of all this cumulative news.

Only 1 in 10,000 drug applications receives an FDA IND approval. For Imugene to receive 2 in a single day is truly remarkable.

But here, on this joke known as the "ASX", sitting now at a share price of 52 cents, we are actually 12% BELOW the 59 cents we were at before we received the first monumental news of the Merck & Pfizer agreement???????????

How the hell is that possible?

Are the pathetic leaches trading their shares to make a measley2 cents profit responsible? No, those cretins don't have that much sway in the market. So that must mean that it's institutional/broker driven games that are reducing & capping the share price.

Whatmighthaveben probably hit the nail on the head when he wrote on the weekend that it was coming time for Imugene to leave the ASX and list on the NASDAQ. A company like Imugene with it's priceless IP, current cash reserves of AUD$120 million, and huge pipeline of FDA-approved drug candidates - would be worth at least USD$10 Billion (AUD$14 Billion) ... or AUD$2.30 a share.

Congratulations to Leslie, Paul and the tireless IMU team for today's incredibly amazing news.

Expand

PB, even more to say that ALL 5 of IMU's 5 IND application went through first time. Not sure if any other ASX listed or even world wide listed company got a 100% IND approval track record.

Well done Team IMU, what a journey over the past 5-6 years and what a journey still to come.

PB, the sp will end up where it belongs, doesn't matter whether today or another day.

GLTA

IMU Price at posting: 52.5¢ Sentiment: Buy Disclosure: Held
55 Upvote

0 Great analysis

Reply

Top Stories

GRX

GreenX picks up prospective copper project in Germany

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

Is oil undervalued?

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

WGX

Westgold sets its sights on top five producer status through merger with Karora

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

There are more pages in this discussion • 7 more messages in this thread...

First 36 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 5.2¢		Change -0.001(1.89%)		Mkt cap ! $382.1M

Open	High	Low	Value	Volume
5.4¢	5.4¢	5.1¢	$674.9K	12.90M

Buyers (Bids)

No.	Vol.	Price($)
1	45087	5.2¢

Sellers (Offers)

Price($)	Vol.	No.
5.3¢	519803	5

View Market Depth

No.	Vol.	Price($)
1	45087	0.052
11	671034	0.051
81	7658639	0.050
23	3483045	0.049
19	831259	0.048

Price($)	Vol.	No.
0.053	384611	4
0.054	2188679	7
0.055	670630	7
0.056	1929043	11
0.057	1626859	12

Last trade - 16.10pm 02/08/2024 (20 minute delay)

IMU (ASX) Chart

Ann: FDA IND APPROVAL FOR ONCOLYTIC VIROTHERAPY VAXINIA, page-36

GreenX picks up prospective copper project in Germany

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Venture to sniff out high-grade REE targets at Jupiter project, WA

Is oil undervalued?

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Westgold sets its sights on top five producer status through merger with Karora

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: FDA IND APPROVAL FOR ONCOLYTIC VIROTHERAPY VAXINIA, page-36

Top Stories

GreenX picks up prospective copper project in Germany

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Venture to sniff out high-grade REE targets at Jupiter project, WA

Is oil undervalued?

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Westgold sets its sights on top five producer status through merger with Karora

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News